

## **Rhythm Advances ColoSTAT<sup>®</sup> Study 7, adding 2 New Clinical Trial sites**

- ✓ **Two new clinical trial sites added, including Concord Repatriation General Hospital and Bendigo Cancer Centre;**
- ✓ **Dr Emily He and Dr Sam Harris appointed as Principal Investigators at Concord and Bendigo Cancer Centre respectively; and**
- ✓ **Both sites have recruited their first patients.**

**19 January 2021, Melbourne:** Rhythm Biosciences Limited (ASX: RHY) (**Rhythm** or the **Company**) is pleased to confirm that Concord Repatriation General Hospital, based in Sydney's Inner West and Bendigo Cancer Centre based in the Bendigo Hospital, have joined Rhythm's ColoSTAT<sup>®</sup> Clinical Trial. A total of nine clinical trial sites are now appointed as part of the final pathway to commercialise Rhythm's ColoSTAT<sup>®</sup> test-kit, which is aimed to be a globally marketed, low-cost, simple blood test for the detection of colorectal cancer, aimed at mass-market screening.

### **Rhythm CEO, Glenn Gilbert, commented:**

*"The addition of Concord and the Bendigo Cancer Centre to the ColoSTAT<sup>®</sup> clinical trial continues to build on our momentum toward delivering an important world-leading and mass-market simple blood test for the early detection of colorectal cancer."*

### **Concord Repatriation General Hospital**

Concord has both a nationally and internationally acknowledged centre of excellence in colorectal surgery. It services the extensive health network within the Sydney Local Health District, and it is also one of the premier teaching hospitals in NSW and indeed Australia. The Gastroenterology department has a deep experience in clinical trials, conducting over 50 trials in the last 5 years.

### **Dr Emily He, commented:**

*"With colorectal cancer now the leading cause of cancer related deaths for 30-35 year-olds in both male and females in Australia, the time is right for a simple and effective blood test for early detection that can be adopted by all ages of the population on a mass scale."*

### **Bendigo Cancer Centre**

Based within the Bendigo Hospital, the state-of-the-art Bendigo Cancer Centre has a dedicated clinical trials research unit which consists of a multidisciplinary team participating in international and national clinical trials with the affiliation of Cancer Trials Australia.

Bendigo Health is a leading regional health service, with a catchment area covering a quarter of the size of Victoria. Referrals to the Cancer Centre may come for various regional settings including areas such as Mildura, Echuca, Swan Hill, Kyneton and Castlemaine.

**Dr Sam Harris, commented:**

*"As a leading regional cancer centre specialising in diagnosing and treating cancer patients, we see first-hand the social, physical and mental impacts that colorectal cancer can have on families, particularly when diagnosed late. With such low participation rates under the current screening system, we are eager to be part of the development of a new simple blood test that has the potential to increase screening compliance and ultimately save lives."*

Rhythm continues to assess the feasibility of both existing and new sites in accelerating the ColoSTAT® Study 7 clinical trial.

With the authority of the Board.

For further information, please contact:

Glenn Gilbert  
Chief Executive Officer  
+61 3 8256 2880

**About Rhythm Biosciences**

Rhythm Biosciences (ASX: RHY) is a transformative, predictive diagnostics company, specialising in early cancer detection. Rhythm's initial business pursuit is centred upon technology originally developed by the CSIRO and involves the development and commercialisation of a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT®, is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT® also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT® is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT® has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Globally, over 850,000 people die from colorectal cancer each year. Colorectal cancer is typically diagnosed at a later stage when there is a poor prognosis for long-term survival. Annual estimated unscreened 50-74-year old's is estimated at +130m for the US, EU and AU alone, with this market potential being more than \$6.5b.